Search Results - "Diessner, J"

Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison by Marko, Tracy A., Diessner, Brandon J., Spector, Logan G.

“…Background Osteosarcoma (OS) is the most common primary malignant bone tumor in many countries, with metastatic disease responsible for most patient deaths…”
Get full text

Establishing semi-automated infection surveillance in obstetrics and gynaecology by Hill, H., Wagenhäuser, I., Schuller, P., Diessner, J., Eisenmann, M., Kampmeier, S., Vogel, U., Wöckel, A., Krone, M.

“…Surveillance is an acknowledged method to decrease nosocomial infections, such as surgical site infections (SSIs). Electronic healthcare records create the…”
Get full text

Imaging for local recurrence of breast cancer by Schlaiss, T., Bott, L., Herbert, S.-L., Bartmann, C., Kiesel, M., Salmen, J., Sauer, S. T., Christner, S. A., Petritsch, B., Grunz, J.-P., Woeckel, A., Löb, S., Diessner, J.

“…Purpose Isolated locoregional recurrence of breast cancer (ILRR) and contralateral breast cancer (CBC) affect up to 20% of all breast cancer (BC) patients in…”
Get full text

To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis? by Herbert, S. L., Wöckel, A., Kreienberg, R., Kühn, T., Flock, F., Felberbaum, R., Janni, W., Curtaz, C., Kiesel, M., Stüber, T., Diessner, J., Salmen, J., Schwentner, L., Fink, V., Bekes, I., Leinert, E., Lato, K., Polasik, A., Schochter, F., Singer, S.

“…Objective In this study, we investigated to which extent patients feel well informed about their disease and treatment, which areas they wish more or less…”
Get full text

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1) by Diessner, J, Bruttel, V, Stein, R G, Horn, E, Häusler, S F M, Dietl, J, Hönig, A, Wischhusen, J

“…The antibody trastuzumab (Herceptin) has substantially improved overall survival for patients with aggressive HER2-positive breast cancer. However, about 70%…”
Get full text

A comparison of risk factors for metastasis at diagnosis in humans and dogs with osteosarcoma by Diessner, Brandon J., Marko, Tracy A., Scott, Ruth M., Eckert, Andrea L., Stuebner, Kathleen M., Hohenhaus, Ann E., Selting, Kim A., Largaespada, David A., Modiano, Jaime F., Spector, Logan G.

“…Background Canine osteosarcoma (OS) is a relevant spontaneous model for human OS. Identifying similarities in clinical characteristics associated with…”
Get full text

International trends in incidence of osteosarcoma (1988‐2012) by Rojas, Gabriela A., Hubbard, Aubrey K., Diessner, Brandon J., Ribeiro, Karina B., Spector, Logan G.

“…Osteosarcoma (OS) is the most common primary bone tumor in children and adolescents. The etiology of OS is largely unknown but may be informed by comparisons…”
Get full text

Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study by Diessner, J., Van Ewijk, R., Weiss, C. R., Janni, W., Wischnewsky, M. B., Kreienberg, R., Hancke, K., Blettner, M., Wöckel, A., Schwentner, L.

“…Purpose Inflammatory breast cancer (IBC) represents a rare and aggressive form of cancer with negative prognosis and high rate of recurrence. The purpose of…”
Get full text

The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer by Swami, Umang, Hong, Agnes, El-Chaar, Nader N, Ramaswamy, Krishnan, Diessner, Brandon J, Blauer-Peterson, Cori J, Sandin, Rickard, Nimke, David, Agarwal, Neeraj

“…We evaluate utilization of treatment intensification of androgen deprivation therapy with androgen receptor pathway inhibitor/docetaxel for metastatic…”
Get full text

Comparative international incidence of Ewing sarcoma 1988 to 2012 by Spector, Logan G., Hubbard, Aubrey K., Diessner, Brandon J., Machiela, Mitchell J., Webber, Beau R., Schiffman, Joshua D.

“…Ewing sarcoma (ES) is the second most common primary bone tumor in children and adolescents. There are few known epidemiological or genetic risk factors for…”
Get full text

Racial and Ethnic Differences in Sarcoma Incidence Are Independent of Census-Tract Socioeconomic Status by Diessner, Brandon J, Weigel, Brenda J, Murugan, Paari, Zhang, Lin, Poynter, Jenny N, Spector, Logan G

“…Epidemiologic analyses of sarcoma are limited by the heterogeneity and rarity of the disease. Utilizing population-based surveillance data enabled us to…”
Get full text

PI3K Inhibitor D-116883 is Effective in In Vitro Models of Ovarian Cancer by HONIG, A, HAHNE, J. C, MEYER, S, KRANKE, P, HAUSLER, S, DIESSNER, J, DIETL, J, ENGEL, J. B

“…D-116883 (Aeterna Zentaris GmbH, Frankfurt, Germany) is an orally effective drug that acts via inhibition of phosphatidylinositol 3-kinase (PI3K). The PI3K/AKT…”
Get full text

Peptidomimetic GnRH Antagonist AEZS-115 Inhibits the Growth of Ovarian and Endometrial Cancer Cells by ENGEL, J. B, HAHNE, J. C, HÄUSLER, S. F. M, MEYER, S, SEGERER, S. E, DIESSNER, J, DIETL, J, HONIG, A

“…AEZS-115 (Aeterna Zentaris GmbH, Frankfurt/M, Germany) is an orally active peptidomimetic antagonist of gonadotropin-releasing hormone (GnRH). In various…”
Get full text

XY gonadal dysgenesis--development of a germ cell tumor: case report by Diessner, J, Stüber, T, Niederle, B, Pawlik, M, Dietl, J, Honig, A

“…Gonadal dysgenesis (GD) is a rare congenital malformation that affects about one in 3,000 births. The authors present a case of a 17-year-old woman with…”
Get more information

Birthweight and site of osteosarcoma development by Diessner, Brandon J., Spector, Logan G.

Get full text

Associations of Socioeconomic Status, Public vs Private Insurance, and Race/Ethnicity With Metastatic Sarcoma at Diagnosis by Diessner, Brandon J, Weigel, Brenda J, Murugan, Paari, Zhang, Lin, Poynter, Jenny N, Spector, Logan G

“…Approximately 10% to 30% of patients with sarcoma present with detectable metastases at diagnosis. However, the extent to which presentation with metastases is…”
Get full text

Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma by Marko, Tracy A., Shamsan, Ghaidan A., Edwards, Elizabeth N., Hazelton, Paige E., Rathe, Susan K., Cornax, Ingrid, Overn, Paula R., Varshney, Jyotika, Diessner, Brandon J., Moriarity, Branden S., O’Sullivan, M. Gerard, Odde, David J., Largaespada, David A.

“…Osteosarcoma is the most common primary bone tumor, with metastatic disease responsible for most treatment failure and patient death. A forward genetic screen…”
Get full text

Acute foeto-foetal transfusion syndrome--case report and review of the literature by Stein, R G, Diessner, J, Frieauff, E, Zollner, U, Rehn, M, Dietl, J, Hönig, A

“…The perinatal morbidity and mortality risk in monochorionic twin pregnancies are 3-5-fold increased compared to those of dichorionic twin pregnancies…”
Get more information

Myocardial infarction in the 34th week of gestation: case report by Diessner, J, Heuer, S, Engel, J B, Frambach, T, Kranke, P, Quaisser, C, Dietl, J, Honig, A

“…Acute myocardial infarction during pregnancy is a rare event that is often associated with a very high maternal mortality, estimated to be from 19 to 37%…”
Get more information

P1-04-05: T-DM1 and Pertuzumab as New Tools for HER2 Specific Antibody-Therapy Against Breast Cancer Stem Cells in HER2−Positive Mammary Carcinoma by Honig, A, Diessner, J, Dietl, J, Wischhusen, J

“…Trastuzumab (Herceptin®) has significantly improved the overall survival of patients with HER2−positive breast cancer. The efficacy of this treatment depends…”
Get full text